Frontlight ResearchEarly access
TerminatedPhase 3
Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia
Key facts
- Who runs it
- Biotest
- Where
- Argentina, Austria, Belgium, Brazil, France, Germany, Hungary, Latvia, Lithuania, Portugal, Slovakia, South Africa, Spain, and Türkiye59 sites in 14 countriesChoose a country to see its sites
- Status
- Terminated
- Phase
- Phase 3
- People taking part
- 107 people enrolled
- Started
- 22 Dec 2022
- Ended
- 5 May 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Trimodulin
- Placebo (human albumin 1%)
- Record updated
- 8 June 2025
- Why it stopped
- Unacceptable delay of trial completion Low recruitment rate
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 25 criteriaShow less
Other criteria
- Main Inclusion Criteria:
- Written informed consent
- Hospitalized, adult (≥ 18 years of age) subjects
- Diagnosis of CAP or COVID- 19 pneumonia (e.g. according to local guidelines) and with radiologic evidence showing new pulmonary lobar or multilobar infiltrates consistent with CAP or COVID-19 pneumonia
- Receiving oxygen supply via low-flow oxygen, high-flow oxygen or on non-invasive ventilation
- Fulfilling at least one clinical respiratory parameter (SpO2 ≤ 94% and/or 100 mm Hg < PaO2/FiO2 ≤ 300 mm Hg)
- Signs of early systemic inflammation based on CRP and coagulation parameter threshold levels; Main Exclusion Criteria:
- Pregnant or lactating women
- Subject on invasive mechanical ventilation and/or extracorporeal membrane oxygenation
- Subject with septic shock and in need for vasopressors
- Severe neutropenia prior to start of treatment
- Hemoglobin >7 g/dL prior to start of treatment
- Pre-existing hemolytic disease
- Pre-existing thromboembolic events (TEEs)
- Subject on dialysis or with severe renal impairment prior to start of treatment
- Subject with end stage renal disease, or known primary focal segmental glomerulosclerosis
- Pre-existing severe lung diseases to current pneumonia
- Pre-existing decompensated heart failure
- Pre-existing hepatic cirrhosis, severe hepatic impairment , or hepatocellular carcinoma
- Known intolerance to proteins of human origin or known allergic reactions to components of trimodulin/placebo
- Selective, absolute immunoglobulin A (IgA) deficiency with known antibodies to IgA
- Known human immunodeficiency virus infection
- Life expectancy of less than 90 days
- Morbid obesity or malnutrition
- Treatment with predefined medications (certain immune modulators or immunosuppressants) before entering the trial
This trial has no sites in United States.
It has sites in 14 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The main objectives of the trial are to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with non-severe community-acquired pneumonia (CAP) or moderate / severe Coronavirus Disease 2019 (COVID-19) pneumonia.
Read full original descriptionShow less
Other objectives are to determine pharmacokinetic (PK) and pharmacodynamic (PD) properties of trimodulin.
The 2 groups in the trial
- TrimodulinTreatment being tested
Trimodulin (human IgM, IgA, IgG solution) for intravenous (IV) administration.
- PlaceboPlacebo, for comparison
Human albumin 1%
Treatment: Placebo (human albumin 1%)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Randomized, Placebo-controlled, Double-blind, Multi-center, Phase III Trial to Assess the Efficacy and Safety of Trimodulin (BT588) in Adult Hospitalized Subjects With CAP Including COVID-19 Pneumonia.
- Record updated
- 8 June 2025